SARS (Severe Acute Respiratory Syndrome) is a type of acute respiratory syndrome. Coronavirus-2 (SARS-CoV-2) is the virus that causes COVID-19, which has spread globally. However, there is no precise drug that can prevent or treat COVID-19 at this time. Researchers from all over the world are striving to find the most effective ways to treat and prevent COVID-19, from repurposing existing medications to developing novel antiviral therapies. A list of repurposed drugs with significant pharmacological effects and therapeutic efficacies in treating COVID-19 patients might be developed, according to fresh research and clinical data on the virologic SARS-CoV-2.
Title : Pathology and patient safety: The vital role of electronic medical record and pathology informatics in error reduction and precision medicine
Consolato M Sergi, University of Ottawa, Canada
Title : mRNA-based systemically delivered directed gene therapy using nanomaterials
A C Matin, Stanford University, United States
Title : Role of nanoformulations in treating Cystic Fibrosis
Bhupendra Gopalbhai Prajapati, Shree S.K.Patel College of Pharmaceutical Education and Research, India
Title : EU GMP annex1 barrier system and PIC/s annex 2A on cell and gene therapy
Richard Denk, SKAN AG, Switzerland
Title : Pro and con to dermpharm and tox assays- 2023
Howard I Maibach, University of California, United States
Title : Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Extracellular vesicles as delivery vehicles of therapeutic compounds
Stefania Raimondo, University of Palermo, Italy
Title : Pediatric brain on cannabinoids: Adverse effects of cannabinoid products in children and adolescents
Peter B Chase, Essentia Health- St. Mary's Medical Center, United States
Title : EBV latent membrane protein 1 augments gammer-delta T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules
Yue liu, Hong Kong Baptist University, China